Russia has announced that its experimental cancer vaccine, Enteromix, has completed preclinical trials, with officials claiming both safety and high efficacy, according to a Newsweek report that raised hope of curing the fatal disease.
Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), told the Eastern Economic Forum in Vladivostok that the vaccine is "now ready for use," pending official approval. She said years of research, including three years of mandatory preclinical testing, showed tumour reductions of 60 to 80% depending on cancer type, alongside improved survival rates.
The vaccine is initially aimed at colorectal cancer, with further development under way for glioblastoma and melanomas, including ocular melanoma, the report noted. Some media outlets have suggested the vaccine achieved 100% efficacy in trials, though Newsweek said it could not verify this claim.
COMMENTS
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ